GESTONORONE CAPROATE Property

Melting point:

123-124°

alpha 

D +13° (chloroform)

Boiling point:

453.43°C (rough estimate)

Density 

1.11

refractive index 

1.4840 (estimate)

storage temp. 

Refrigerator

solubility 

Chloroform (Slightly), Ethyl Acetate (Slightly), Methanol (Slightly)

form 

Solid

color 

Off-White to Pale Beige

Hazard and Precautionary Statements (GHS)

Symbol(GHS)

Signal word

Danger

Hazard statements

H351Suspected of causing cancer

H360May damage fertility or the unborn child

H362May cause harm to breast-fed children

Precautionary statements

P201Obtain special instructions before use.

P202Do not handle until all safety precautions have been read and understood.

P260Do not breathe dust/fume/gas/mist/vapours/spray.

P263Avoid contact during pregnancy/while nursing.

P264Wash hands thoroughly after handling.

P264Wash skin thouroughly after handling.

P270Do not eat, drink or smoke when using this product.

P281Use personal protective equipment as required.

P308+P313IF exposed or concerned: Get medical advice/attention.

P405Store locked up.

P501Dispose of contents/container to..…

GESTONORONE CAPROATE Chemical Properties,Usage,Production

Originator

Depostat,Schering AG

Uses

Gestonorone Capronate, is a pro-drug of Gestonorone, which is a steroidal progestin. It has been shown to have accelerated body weight gain and caused the atrophy of the prostate, uterus, and seminal vesicles in rats. It is also an inhibitor of the reductive pathway of Testosterone (T155000) metabolism.

Uses

Gestonorone Caproate, is a pro-drug of Gestonorone, which is a steroidal progestin. It has been shown to have accelerated body weight gain and caused the atrophy of the prostate, uterus, and seminal vesicles in rats. It is also an inhibitor of the reductive pathway of Testosterone (T155000) metabolism.

Definition

ChEBI: Gestonorone caproate is an organic molecular entity.

Manufacturing Process

2 Methods of producing of 17-α-hydroxyl-19-norprogesteron-17-capronate:
1. To a solution of 1.0 g 17-α-hydroxy-19-norprogesteron in 32 ml capronic acid anhydride 1.32 g p-toluesulfonate (1 mole hydrate) were added, and allowed to stand for 3 h at 37°C. To the solution 1.43 ml conc. hydrochloric acid in 143 ml methanol were added and all this also for 1 h was left under N2. Then mixture was washed with water and treated with ether. Ether extract was washed with water, and dried with Na2SO4. After that ether was distilled and residue was recrystallised with isopropyl ether. 1.1 g of 17-α-hydroxyl-19- norprogesteron-17-capronate was obtained, melting point 123°-124°C.
2. 2.0 g 3-methoxy-17α-hydroxy-17β-acetyl-δ2,5(10)-oestradien, 60 ml capronic acid anhydride, 2.6 g p-toluensulfonate and 18.0 g water were mixed and left for 6 h at room temperature. Then solution obtained was treated ether and sodium bicarbonate and washed with water. Etheral solution was dried over sodium sulfate. After distillation of ether 3.1 g 3,17α-dihydroxy- δ3,5-19-norpregnadien-3,17-dicapronate was produced.
To solution of 3.1 g 3,17α-dihydroxy-δ3,5-19-norpregnadien-3,17-dicapronate in 250 ml methanol 2.5 g conc. hydrochloric acid were added and mixture was left for 1 h. Then mixture was filtered and residue was washed. After recrystallisation with isopropyl ether 17-α-hydroxyl-19-norprogesteron-17- capronate was obtained, melting point 121°-123°C.

Therapeutic Function

Progestin